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p2 1WAF1/CIl expression in gestational trophoblastic
disease: correlation with clinicopathological
parameters, and Ki67 and p53 gene expression
A N Y Cheung, D H Shen, U S Khoo, L C Wong, H Y S Ngan
Abstract
Background-The p221WAFlCIPi gene medi-
ates growth arrest by inhibiting G, cyclin
dependent kinases and has been consid-
ered as a downstream effector of the
tumour suppressor gene p53.
Aim-To analyse the role of p21WAF'ICIP1 in
gestational trophoblastic disease.
Methods-The immunohistochemical ex-
pression of p21WAF1ICIP1 gene was measured
in 33 placentas, 28 partial hydatidiform
moles, 54 complete hydatidiform moles,
and 13 choriocarcinomas in paraffin wax
embedded tissue. The results were corre-
lated with p53 (DO7) and Ki67 (MIB1)
immunoreactivity as well as clinical
progress.
Results-p21"CPl immunoreactivity was
found predominantly in the nuclei of the
syncytiotrophoblasts. p21WAF1ICIPI protein
expression correlated with gestational age
in normal placentas (p = 0.0001) but not
in hydatidiform moles (p = 0.89). Com-
plete hydatidiform moles and chorio-
carcinomas had a significantly higher
p21WAFl'CIPI expression compared with nor-
mal placentas and partial hydatidiform
moles (p < 0.001); there was no difference
between placentas and partial hydatidi-
form moles. No correlation between
p21WAFIICIPI expression and either the prolif-
eration (Ki67) index (p = 0.34) or p53 pro-
tein accumulation (p = 0.68) was
demonstrated. There was no significant
difference (p > 0.05) in p21WAF1/CIP1 expres-
sion between the 17 patients who devel-
oped persistent gestational trophoblastic
disease and those who did not.
Conclusions-This study suggests that
p21WAFUCIPl expression in trophoblastic dis-
ease may be induced by a p53 independent
pathway. The proliferative activity of
gestational trophoblastic diseases might
not be determined solely by the control of
the cell cycle operated by p21WAF11CIP1.
p21WAF11CIPI expression is not an accurate
prognostic indicator of gestational tro-
phoblastic disease.
(T Clin Pathol 1998;51:159-162)
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The WAF1 growth suppressor gene, also
known as CIP1, encodes a 21 kDa protein
p21WAFI/CIPI . This protein is an inhibitor of the
cyclin dependent kinases (CDKs), the activa-
tion of which is important for cell cycle
progression. 12 p21WAFI/CIPI expression is in-
duced by wild-type p53 but not the mutant p53
gene product.2`' Thus, it is considered as a
downstream effector of p53, responsible for the
antiproliferative, apoptotic, and tumour sup-
pressor effects of p53.3
Gestational trophoblastic disease is a hetero-
genous group of lesions including complete
and partial hydatidiform moles, invasive moles,
choriocarcinoma, and placental site tropho-
blastic tumours. Some of these lesions are true
neoplasms, whereas others may be abnormally
formed placentas that have a predisposition to
neoplastic transformation of the trophoblast.
The pathogenesis and factors predicting the
progress of these diseases remain uncertain.6 7
In previous studies, we have demonstrated
the absence of p53 mutation in hydatidiform
moles as well as the overexpression ofwild-type
p53 RNA and protein in hydatidiform moles
and choriocarcinomas compared with normal
placentas8 (Cheung et al, unpublished data).
There are no published data concerning the
role of p2 1WAF1CIPi in the normal placenta and
gestational trophoblastic disease. We investi-
gated the immunohistochemical expression of
p21WAFlICIPI in 33 placentas and 95 cases of
gestational trophoblastic disease. Our aim was
to evaluate p2 1WAF1 CIP expression in relation to
p53 protein expression, proliferative activity,
and other clinicopathological characteristics,
especially the clinical progress of the patients,
in an attempt to clarify the role of p2 1WAFicIpi in
gestational trophoblastic disease.
Methods and materials
The pathology reports of patients with a diagno-
sis of complete hydatidiform mole, partial hyda-
tidiform mole, and choriocarcinoma treated at
the Queen Mary Hospital, University of Hong
Kong were reviewed. Thirty three placentas, 28
partial hydatidiform moles, 54 complete hyda-
tidiform moles, and 13 choriocarcinomas with
available paraffin wax blocks were selected. The
gestational age of the placentas ranged from
seven to 42 weeks, while that of hydatidiform
moles ranged from eight to 28 weeks. Some of
these cases had been investigated previously for
p53 gene status as well as p53 (DO7) and Ki67
(MIB1) immunoreactivity" (Cheung et al,
unpublished data). The histological features of
these cases were assessed using generally agreed
and accepted diagnostic criteria.67
The tissues included uterine curettagings
and blocks from hysterectomy specimens, all of
which were routinely fixed in 10% formalin





























Cheung, Shen, Khoo, et al
4p~~~
Figure 1 Immunoreactivity for p2l"FI'"' is confined to the nuclei of the syncytiotrophoblasts in both (A) complete and (B) partial hydatidiform moles.
The positive nuclei are heavily stained.
sections (4 ,um) were dewaxed and rehydrated.
Endogenous peroxidase was blocked using 3%
H202 in methanol. After microwave pretreat-
ment for antigen retrieval,9 monoclonal mouse
antibodies for p2 1WAFl CIPi (Calbiochem, Massa-
chusetts, USA) was applied at a 1/30 dilution
and incubations were performed overnight at
4°C. Immunohistochemistry was performed
using the ABC immunoperoxidase method
(Dako, High Wycombe, Bucks, UK). Bioti-
nylated sheep antimouse antibody was used as
the linker molecule and diaminobenzidine/
hydrogen peroxide was used as chromogen. A
light haematoxylin counterstain was used. Sec-
tions were dehydrated in alcohol, cleared in
xylene, and mounted.
Sections were examined at high power
(x400) and 20 fields were chosen at random for
each section. In each case, a quantitative
estimate of the nuclear labelling index for
p2 IWAFlICIPI immunoreactivity was made by
scoring positive nuclei/total number of nuclei
counted in a minimum of 300 trophoblastic
cells. The syncytiotrophoblast and cytotro-
phoblast were evaluated separately. The
p21 WAFI/CIPI nuclear labelling index was ex-
pressed as a percentage of the total number of
nuclei counted. In effect, 2000 syncytiotro-
phoblasts and cytotrophoblasts were counted
in each case. Normal colonic tissue was used as
a known positive control and negative controls
were included by substituting Tris buffered
saline for the primary antibody.
Follow up data were available for 71 patients
with partial and complete hydatidiform moles.
Persistent gestational trophoblastic disease was
diagnosed if there was a plateau in human
chorionic gonadotrophin (hCG) concentra-
tions for four weeks or if there was a further
increase in 0-hCG for three consecutive weeks
when pregnancy was excluded.'0 According to
these criteria, four patients with partial hyda-
tidiform moles and 13 patients with complete
hydatidiform moles were diagnosed as having
persistent gestational trophoblastic disease.
Statistical analysis of p2 IWAFI/CIPl expression
among the four groups of trophoblastic tissues
as well as correlation with p53 and Ki67
immunoreactivity was performed with the
Mann-Whitney and Pearson tests.
Results
Immunostaining for p2 1WAFI/CIl protein prod-
uct was predominantly found in the nuclei of
syncytiotrophoblast cells in the normal placen-
tas, partial hydatidiform moles, complete
hydatidiform moles, and choriocarcinomas (fig
1). Mitotic figures were not immunoreactive
for p2 1WAFI/CIPI protein. Occasional stromal cells
in the chorionic villi and the decidual glandular
cells showed weak immunoreactivity for
p2 1WAFI/CIPI, while the endothelium and de-
cidual stromal cells were negative. Regional
variation in staining of trophoblast cells was
observed in the same section.
The staining was found to be heterogeneous
in the different groups of trophoblastic tissue
studied. Table 1 shows the wide range of varia-
tion in the p21WAFICIPI immunoreactivity for
each group of patients. The complete hydatidi-
form moles and choriocarcinomas had a
significantly higher p2 1WAFI/CIPI expression com-
pared with normal placentas and partial hyda-
tidiform moles (p < 0.001), while there was no
difference between placentas and partial hyda-
tidiform moles (table 2).
The normal placentas and the hydatidiform
moles were divided into two groups based on
their gestational age (< 20 weeks and > 20
weeks). The p21WAFlcIPi indices of each of
these groups were compared. p2 1WAF/CIPI
protein expression correlated with gestational
age in normal placentas (p = 0.0001), with
higher expression in early gestation. No such
Table 1 p21 WAFI I'PI index (%/ ofpositively stained
nucleiltotal number of nuclei counted)
Number of
cases Mean (SD) (Go)
Placentas 33 5.2 (8.7)
Partial hydatiform moles 28 9.8 (9.3)
Complete moles 54 20.7 (5.0)
Choriocarcinomas 13 23.3 (20.1)
Table 2 Comparison ofp21 WAFI("I" indexes






PM, partial hydatiform moles; CM, complete moles; CCA,
choriocarcinomas.
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correlation was observed in partial hydatidi-
form moles or complete hydatidiform moles
(p = 0.89).
p21WAFI/CIPI expression was found to be
independent of p53 protein accumulation
(p = 0.68). Cases with a high Ki67 index
seemed to show high p2 1WAFI1CIPl immunoreac-
tivity; however, no significant difference was
demonstrated (p = 0.34). There was also no
statistical correlation (p > 0.05) in p2 1WAFI/CIPI
expression between the 17 patients who re-
quired chemotherapy and the 54 patients with
spontaneous regression of the disease.
Discussion
Deregulation of cell proliferation and differen-
tiation is important in neoplastic transforma-
tion. p2lWAl c'Pi is known to be related to the
control of proliferation and differentiation of
cells. In normal cells, p21 WAFI/CIPi exists in
quaternary complexes with cyclin, CDK, and
proliferating cell nuclear antigen (PCNA).
p21 ``'P1 can induce GI arrest and block entry
into the S phase by inactivating CDKs or by
inhibiting the activity of PCNA." On the other
hand, induction of p21WAFICIPI expression has
been demonstrated during differentiation of
various cell types, both during embryological
development'2 13 and in in vitro experiments.5
Although the expression of p21WAFl/CIPI varies
among different human tissues, it occurs mainly
in quiescent cells.14 For example, p21WAFI1CIPI
immunoreactivity in colonic normal mucosa
and adenomas was seen in the superficial third
of the crypts (maturation compartment) and in
surface (terminally differentiated) epithelium.'5
Thus, p21WAFI/CIPI may be important in the main-
tenance ofgrowth arrest in terminally differenti-
ated cells by inhibiting DNA synthesis.5 12
In this study on trophoblastic tissues,
p21 WAFI/CIPI immunoreactivity in normal pla-
centa and gestational trophoblastic disease,
irrespective of gestational age, was demon-
strated mainly in the terminally differentiated
syncytiotrophoblast, while that for p53 and the
proliferation marker Ki67 was found almost
exclusively in the germinal layer of
cytotrophoblast.8 9 These results suggest that
p21WAFI/CIPI might be associated with the senes-
cence and terminal differentiation of tropho-
blastic tissue and is in agreement with the con-
ventional belief that the syncytiotrophoblast is
the differentiated zone of the placenta.
There are two issues that we would like to
address: what initiates the overexpression of
p21WAF in gestational trophoblastic dis-
eases, especially complete hydatidiform moles
and choriocarcinomas; and what are the
biological consequences of p21 WAFI/CIPi overex-
pression.
Although p21WAFI/CIPI was first established as
a negative regulator of the cell cycle through a
p53 dependent pathway,""2 6induction- ofp21lWAF1/CIP can also be produced by p53
independent mechanisms.'7 '` In trophoblastic
tissues, there appears to be a higher expression
of p21 WAFI CIPi with increasing expression of
wild-type p53. However, the correlation did
not reach significance (p = 0.68). While these
data do not exclude a component of p53
dependent p21lWAFi CIP expression, it is likely
that other p53 independent mechanisms are
operating.
A review of the literature also shows a lack of
correlation between p21WAFI/CIP expression and
p53 status in cancers of the lung, stomach,
pancreas, breast, and ovary.20-25 A finding that is
of particular interest is the p53 independent
induction of p2l"' Cpl expression during
terminal differentiation in various cell
lineages.'2 13 In differentiated cells, such as are
found in the syncytiotrophoblast, p53 inde-
pendent p2 1WAF1'C'P expression is probably
involved in cell cycle withdrawal. p21WAP1 CIPi
expression may also be induced by other
factors related to differentiation and growth
arrest.5 Epidermal growth factor (EGF) and
fibroblast growth factor (FGF) have been
found to induce p21WAFI/cIpI expression.'7
One question that has not been answered by
this study is the functional status of the
p21 WAFI/CIPI protein found to be overexpressed
in the trophoblastic tissue. It is known that
mutations ofthe p21WAFI/CIPI gene can abolish its
tumour suppressor activity.26 However, no
mutations of the p21 WAFI/CIPI gene have been
detected in various studies on carcinomas of
the lung, pancreas,27 oral cavity,28 and colon,29
as well as melanomas30 and the study of
Shiohara et al, which investigated 351cases of
14 different types of human malignancy.3'
Future sequencing studies may be necessary to
determine whether p2 IWAF1 CIPI mutation occurs
in gestational trophoblastic disease.
As p2 1 WAFPICIPI negatively regulates cell cycle
progression, an inverse correlation between
p21 expression and proliferative activity or
malignant behaviour would be expected. In
gestational trophoblastic disease, the pattern is
complex. At the single cell level, p21 WAFI/CIPI and
MIB1 immunoreactivity were observed sepa-
rately in the syncytiotrophoblast and cytotro-
phoblast, respectively. Such a mutually exclu-
sive pattern involving p21WAFl CIP1 and Ki67
expression has also been observed in colonic"5
and gastric20 tissues. p21 WAFI/CIPI expression in
early placentas, which display more active tro-
phoblastic proliferation, is higher than in
mature placentas, where the proliferative activ-
ity is lower.9 32 3 Yet, statistically significant
direct correlation between p21 WAFI/CGPl expres-
sion and proliferative activity could not be
established in gestational trophoblastic disease.
This lack of correlation between p21WAFICIlP
expression and the proliferative (Ki67) index has
also been reported in cancers of the stomach,
colon, breast, and ovary.'5 20 23-25 34 Yasui et al
suggested that tumour cells might have escaped
terminal differentiation and growth arrest by
becoming refractory to the inhibitory signals
from p21 WAFI/CIPI.20 Moreover, proliferation and
progression of trophoblastic tissues may be
regulated by factors other than p21IWAF1CIP"
Association of p21 WAFI/CIPI overexpression
with tumorigenesis has been well established.
In most neoplasms, p21 WAFI/CIPI protein and
RNA were expressed at higher levels than in the
corresponding normal tissues. For example,
the levels of p21WAFI 'c'P expression in normal or
161
Cheuing, Sheni, Khoo, et al
reactive brain and lung tissue were much lower
than in gliomas or pulmonary carcinoma.
Complete hydatidiform mole has a higher
potential to develop persistent gestational
trophoblastic disease compared with partial
hydatidiform mole and, according to the beliefs
of most gynaecological oncologists, only com-
plete hydatidiform mole will develop into
choriocarcinoma.6 Our findings that complete
hydatidiform mole and choriocarcinoma have a
higher level of p21""' expression concur
with the association between p21lSAF" "' ex-
pression and tumorigenesis.
We were thus interested to see whether
p2 1\AI ( t expression can predict the clinical
behaviour of trophoblastic diseases. Our previ-
ous studies on PCNA, Ki67, and p53 showed
that these indices could not predict the
progression of molar pregnancies to persistent
trophoblastic disease' " (Cheung et al, unpub-
lished data). In this study, there was no signifi-
cant difference in the p2 1 WAFI"C index between
the patients who developed persistent
gestational trophoblastic diseases and those
who did not. Thus, the p21\AW CIPI index is not
useful in predicting the prognosis of molar
pregnancies.
To conclude, our study demonstrates a com-
plex relation between p2 1\WAFI CIPI expression
and phenotypes of gestational trophoblastic
disease. p21\IAN C(PI is found to be overex-
pressed in gestational trophoblastic disease
compared with the normal placenta, although
p21\x`A"` expression could not predict the
clinical progress of the disease. p21 WAF1 (PI
expression did not correlate with proliferative
activity or p53 expression. This is compatible
with the observation that p21IWAF CIPI, p53, and
Ki67 immunoreactivity operate in different
populations of trophoblasts. This also suggests
that the proliferative activity in trophoblastic
tissue may be controlled by factors other
than p2 1iWA'F'cl. The lack of correlation with
p53 expression supports the possibility that
p2 1\xA `"" is being induced at least in part by
p53 independent mechanisms.
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